Construction of efficacy prediction model for T-DXd treatment of HER2-positive and HER2-low expression breast cancer based on hematological indicators: A real-world study.
Blood count monitoring during breast cancer treatment helps predict which patients will benefit most from therapy.
BACKGROUND: This study explores hematological changes during trastuzumab deruxtecan (T-DXd) treatment in HER2-positive and HER2-low breast cancer patients, aiming to develop an efficacy prediction model for personalized ... Our predictive model demonstrates strong performance in identifying patients suitable for treatment, highlighting that rigorous monitoring of hematological indicators is critical for mitigating risk and upholding safety ...
What the study was
- Study design
- Retrospective study
- Population
- cancer patients
- Sample size
- 114
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Computational biology and chemistry
Why it surfaced
Score 6/10 [PROMISING_PRELIMINARY]: Retrospective study (Journal Article) matched 'CBC-based diagnostics and machine learni'. Components — novelty:1/3, relevance:3/3, design:1/2, population:1/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.